Although the precise targeting of cancer cells remains challenging, advancements in nanotechnology, histological techniques, and a deeper understanding of cancer biology may enable these therapeutic strategies to be translated into clinical practice, offering new hope to patients with FSH-related ovarian cancer or even other cancers with these pathogenic pathways. This evidence concerns the gene BRD2 and cancer.